ArticleBritish journal of haematology2026

Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.

Maria Kislova et al.PubMed ↗Publisher ↗

No numbers read from the abstract.